# Genprex (GNPX) — News

GNPX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gnpx/news

## Recent headlines

- [Andelyn Biosciences: To scale manufacturing for GenPrex's diabetes gene therapy program](https://www.ainvest.com/news/andelyn-biosciences-scale-manufacturing-genprex-diabetes-gene-therapy-program-2609) — AInvest Wire, Sep 1, 2026
  GenPrex, Inc. (NASDAQ: GNPX) has announced a strategic collaboration with a leading U.S.-based Contract Development and Manufacturing Organization (CDMO) to scale the manufacturing of its diabetes gene therapy program. This partnership marks a critical step in transitioning the company’s…
- [Genprex - expects to complete validation studies by end of 2026](https://www.ainvest.com/news/genprex-expects-complete-validation-studies-2026-2608) — AInvest Wire, Aug 3, 2026
- [Genprex Inc files for mixed shelf of up to $250 mln – SEC filing](https://www.ainvest.com/news/genprex-files-mixed-shelf-250-mln-sec-filing-2606) — AInvest Wire, Jun 5, 2026
- **Important** — Genprex Shares Climb After First Patient Dosing in Reqorsa-Tagrisso Trial — AInvest Wire, Feb 5, 2024
  Genprex Shares Climb After First Patient Dosing in Reqorsa-Tagrisso Trial Genprex Shares Climb After First Patient Dosing in Reqorsa-Tagrisso Trial Genprex, a clinical-stage gene therapy company, has announced the first patient dosing in its Phase 2a expansion study of REQORSA® Therapy in…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).